Legitimacy in Motion

Real-World Evidence Does Not Replace HTA.

It Outgrows It.

HTA was designed to answer a question before reality could.

RWE answers it

after reality has spoken.

This is not competition.

It is sequence.

Where HTA is unavailable,

RWE does not act as a substitute checkbox. (no...)

It acts as a legitimacy engine.

Confidence accumulates not because permission was granted,

But because outcomes persist.

In this model, HTA is no longer the gatekeeper of value!

It becomes one potential witness among others!

(yes) And witnesses... can arrive late!

The Near Horizon Legitimacy Model.

A new pathway is already forming,

quietly, unevenly, but undeniably.

1.

Restricted National Formulary Inclusion

Not as validation, but as access to observation.

2.

Price Accessibility

as

Ethical Signal.

3.

Embedded, Prospective RWE

Designed before launch

Collected

continuously

Visible to the system,

not curated for persuasion.

4.

Confidence Accumulation Over Time

Year one: signal!

Year two: repetition!

Year three: durability!

This is not defiance of HTA!

It is alignment... alignment with reality!

Time works against absence,

But it works, oh it works for observation!

When a product has years of consistent outcomes,

patient trust, And no HTA decision...

What exactly is HTA withholding?

Permission?

Or

acknowledgement?

One of those matters far less than it once did.